Vanguard Group
RVLP

Vanguard Group’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Vanguard Group’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-246,353
Closed -$21.3K – 4578
2023
Q3 		$21.3K Hold
246,353
– – ﹤0.01% 4492
2023
Q2 		$138K Hold
246,353
– – ﹤0.01% 4363
2023
Q1 		$281K Hold
246,353
– – ﹤0.01% 4266
2022
Q4 		$276K Buy
246,353
+23,918
+11% +$38.1K ﹤0.01% 4242
2022
Q3 		$467K Hold
222,435
– – ﹤0.01% 4231
2022
Q2 		$302K Buy
222,435
+14,493
+7% +$21K ﹤0.01% 4407
2022
Q1 		$352K Hold
207,942
– – ﹤0.01% 4447
2021
Q4 		$225K Sell
207,942
-2,492
-1% -$4.04K ﹤0.01% 4545
2021
Q3 		$621K Hold
210,434
– – ﹤0.01% 4346
2021
Q2 		$634K Sell
210,434
-57,973
-22% -$177K ﹤0.01% 4232
2021
Q1 		$875K Buy
268,407
+7,197
+3% +$29.6K ﹤0.01% 4043
2020
Q4 		$1.08M Buy
261,210
+6,786
+3% +$39.1K ﹤0.01% 3810
2020
Q3 		$1.38M Buy
254,424
+309
+0.1% +$1.78K ﹤0.01% 3587
2020
Q2 		$1.71M Buy
254,115
+27,824
+12% +$136K ﹤0.01% 3473
2020
Q1 		$719K Buy
226,291
+120,259
+113% +$640K ﹤0.01% 3584
2019
Q4 		$741K Buy
106,032
+664
+0.6% +$3.54K ﹤0.01% 3704
2019
Q3 		$405K Sell
105,368
-16,231
-13% -$55K ﹤0.01% 3859
2019
Q2 		$462K Sell
121,599
-222
-0.2% -$738 ﹤0.01% 3840
2019
Q1 		$438K Buy
121,821
+8,137
+7% +$59.9K ﹤0.01% 3796
2018
Q4 		$881K Buy
+113,684
New +$910K ﹤0.01% 3597

Other funds holding RVLP

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Vanguard Group's RVLP Position: Q4 2023 in Review

Vanguard Group sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2023, closing a stake of 246,353 shares — an estimated $21.3K sold.

Vanguard Group first reported a position in RVLP in Q4 2018 and held it in 20 quarters. The position peaked at $1.71M in Q2 2020. 3 funds tracked by Wall St. Rank hold RVLP as of Q4 2023.

  • Vanguard Group reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Vanguard Group sold 246,353 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2023, an estimated $21.3K.
  • Vanguard Group first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 20 quarters.
  • Vanguard Group's RVL Pharmaceuticals plc Ordinary Shares position peaked at $1.71M in Q2 2020.
  • 3 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2023.

Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.